{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "CNTA",
  "name": "Centessa Pharmaceuticals plc",
  "url": "https://orbyd.app/dossiers/CNTA/",
  "json_url": "https://orbyd.app/dossiers/CNTA.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Terminal special situation, unchanged: Lilly's $38.00 cash plus up-to-$9.00 non-transferable CVR scheme became effective 2026-06-24, last Nasdaq print was 2026-06-23, and Form 15-12G is dated 2026-07-06. The only live development is class-level — FDA approved Takeda's OX2R agonist ORZEYFUL on 2026-08-05 — and it accrues to TAK/ALKS/LLY, not to any CNTA instrument.",
  "invalidation_trigger": "A daily close below $38.00 cannot print: the ADSs delisted from Nasdaq on 2026-06-24 into $38.00 cash plus a non-transferable up-to-$9.00 CVR, last session 2026-06-23 at $40.50, Form 15-12G dated 2026-07-06. No US-listed equity remains and the CVR does not trade.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "m-and-a-special-situations",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "No US-listed equity remains: Centessa ADSs delisted from Nasdaq 2026-06-24; the Form 15-12G deregistration filing is dated 2026-07-06.",
    "The up-to-$9.00 CVR is non-transferable and went to scheme record holders; it cannot be bought, sold or hedged after the close.",
    "Any CNTA price still rendered by a data vendor is the 2026-06-23 final session print, not a live market quote.",
    "Holder base was institutional (Samlyn, Bain, Perceptive), so the June tape was deal arbitrage; no retail-squeeze mechanics ever applied here.",
    "Orexin class read-through now flows to Takeda (ORZEYFUL), Alkermes (alixorexton) and Lilly (ORX750) — never back to this symbol."
  ],
  "body_markdown": "## Current Thesis\nNothing in the last month reopened this. Eli Lilly's UK scheme of arrangement — **$38.00 cash per share plus one non-transferable contingent value right worth up to $9.00** — became effective on 2026-06-24 after the High Court of England and Wales sanctioned it on 2026-06-22; the acquirer vehicle was LDH XV Corporation, a wholly owned Lilly subsidiary. The final Nasdaq ADS session was 2026-06-23. The only genuinely new filing since the prior note is the **Form 15-12G dated 2026-07-06** on SEC EDGAR, which suspends the reporting obligations and starts the clock on termination of registration. The only genuinely new *news* is class-level and lands elsewhere: on 2026-08-05 the FDA approved Takeda's ORZEYFUL (oveporexton) for narcolepsy type 1, the first approved OX2R agonist. That event moves Takeda, Alkermes and Lilly. It cannot move a security that no longer trades.\n\n## Bull Case\n- **The consideration cleared in full.** No financing condition, no antitrust hang-up, no re-cut: sanction 2026-06-22, effective 2026-06-24, cash fixed at $38.00 per share (CNTA 8-K, 2026-06-24). The announcement print on 2026-03-31 was +45%, against a headline value around $7.8B and roughly a 40% premium.\n- **The final tape carried a CVR mark.** The last adjusted close, 2026-06-23, was $40.50 — above the $38.00 cash consideration, so the market was still assigning residual value to the up-to-$9.00 CVR into the close. That is an inference from the price relationship, not a disclosed CVR valuation.\n- **The mechanism got a regulatory precedent on 2026-08-05.** FDA approval of oveporexton, an oral orexin-receptor-2 agonist, on the strength of two randomized double-blind placebo-controlled Phase 3 trials in 273 NT1 adults (Takeda, 2026-08-05), establishes that the class can clear a US review. ORX750's registrational path sits inside Lilly now, and the CVR milestones ride on it.\n- **The holder base did not fight.** The 2026-06-12 shareholder vote passed with the Samlyn / Bain / Perceptive institutional register in place — no holdout campaign, no appraisal drama, no delayed effective date.\n\n## Bear Case\n- **There is no instrument.** Delisted 2026-06-24; Form 15-12G dated 2026-07-06. Any CNTA quote a data vendor still renders is the 2026-06-23 print sitting on a dead feed.\n- **The CVR is non-transferable.** Record holders at the scheme hold a contingent claim of up to $9.00 across staged milestone payments. It cannot be bought, sold, hedged or expressed after close, so no positive ORX750 outcome converts into a tradable move in this symbol.\n- **ORX750 is now a follower.** With ORZEYFUL approved for NT1 on 2026-08-05 and Alkermes running the Phase 3 Brilliance program in NT1/NT2 with FDA Breakthrough Therapy designation for alixorexton, the commercial slope for a later OX2R entrant is steeper than it looked when the deal was struck on 2026-03-31.\n- **The sell-side marks are archaeology.** Needham. Those were resets to deal price plus a thin CVR mark and have no live referent.\n\n## Setup & Price Structure\n- **Narrative state: DEAD**, dated three ways — last trade 2026-06-23, scheme effective 2026-06-24, deregistration filing 2026-07-06. This is not a fading narrative; the price-discovery mechanism was removed.\n- **The technical snapshot is frozen, and reading it as momentum is a category error.** The basis close of $40.50 is simultaneously the 52-week high (0.0% from high), the 3-month return of 45.2% is the 2026-03-31 announcement gap, and RSI(14) at 71.1 is the final session's residue. None of these update.\n- **Crowding and positioning observables, stated plainly**: no float in public hands, so no short interest to cover and no squeeze mechanics; no earnings date, because reporting obligations were suspended with the Form 15; no insider Form 4s can print post-deregistration; no issuance risk, since the ATM program and the Oxford Finance loan were terminated at close. The absence of every standard positioning observable is itself the structural fact.\n- **Historical levels for the record**: $38.00 cash was the anchor floor from 2026-03-31 onward; the $40–42 analyst marks bracketed cash plus risk-adjusted CVR; the pre-bid base sat around $27–28 and was the only real downside reference the deal-break tail ever had.\n\n## Catalyst Calendar (next 30 days)\n- **No dated catalyst falls inside the next 30 days for this security.** There is no print, no vote, no listing event.\n- **~2026-10-04 (est.)** — termination of ADS registration takes effect on the standard 90-day path from the 2026-07-06 Form 15-12G filing. Administrative; it closes the last public-disclosure channel on the entity.\n- **~2026-12-31 (est.)** — ORX750 registrational/CRYSTAL-1 program progress, guided by pre-deal Centessa disclosure to H2 2026, now reported (if at all) through Lilly's pipeline table. Relevant to CVR milestone determination, not to a share price.\n- **Undated** — Alkermes Brilliance Phase 3 readouts and any ORZEYFUL launch metrics from Takeda set the class benchmark ORX750 will be measured against.\n\n## What Would Change Our Mind\nOnly an unwind of the scheme itself would put a tradable CNTA share back on a US exchange — a court-ordered rescission of the 2026-06-22 sanction, or a Lilly decision to re-list the entity. Neither appears on any docket or filing as of 2026-08-08. Expressed as the gradeable condition the record grades: **a daily close below $38.00 cannot print**, because no US session exists to produce one; the last was 2026-06-23 at $40.50. Secondary conditions that would matter if the structure ever changed: a CVR milestone payment notice (which pays scheme record holders and creates no market exposure), or a re-registration filing reversing the 2026-07-06 Form 15-12G. Absent those, the correct stance toward this symbol is to stop treating it as a live name.\n\n## Correlation Notes\n- **Zero live beta to XBI / IBB.** From 2026-03-31 to 2026-06-23 the ADS traded as a deal-pinned instrument with near-nil sector correlation; after 2026-06-24 there is no series to correlate.\n- **The orexin read-through has re-routed.** Class sentiment now expresses through Takeda (ORZEYFUL approved 2026-08-05), Alkermes (alixorexton, Phase 3 Brilliance, Breakthrough Therapy designation in NT1) and Lilly (ORX750 as an acquired asset). CNTA is a source of read-through for those names, never a recipient.\n- **Deal-arb comp**: the 2026-03-31 tape that lifted CNTA also carried Apellis on the Biogen bid at $41/share — a reminder that the mid-cap biotech takeout window of spring 2026 was the driver of the move, and that window's later entries, not this one, are where the analog is still live.",
  "first_seen": "2026-04-19",
  "last_analyzed": "2026-08-08T14:33:50+00:00",
  "last_synthesized": "2026-08-08",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}